Abstract
Diabetes mellitus (DM) is a common endocrine disease that can cause damage to tissues and organs throughout the body. Glycosylated haemoglobin (HbA1c) is considered to be the gold standard for assessing glycaemic control and treatment outcomes in patients with diabetes, but there is individual variability that affects the accurate interpretation of blood glucose. The glycosylated haemoglobin variability index (HGI) is a measure of individual variability in HbA1c and can be used in the management and treatment of patients with DM. In this paper, the relationship between HGI and chronic complications of DM is reviewed and discussed, with the aim of providing a more individualized and accurate reference for clinical management of blood glucose and risk assessment of chronic complications in DM patients, reducing and delaying the occurrence of chronic complications of diabetes and improving the quality of life of DM patients.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: International Journal of Biology and Life Sciences
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
